Meryx is developing small-molecule, orally-bioavailable RTK inhibitors that inhibit growth and initiate anti-tumor immunity in hematologic and solid malignancies.
Company Details
Year founded
2013
Employment range in NC
US headquarters
North Carolina
Global headquarters
United States
Primary site activity
All company activities
Potential end market(s)
Products under development
MRX-2843, small molecule, inhibitor of MerTK